The Steering Committee regularly select the most relevant and up-to-date publications for rapid review. This includes a brief summary highlighting the key points of the paper and a slide deck going into more detail of the data.
Cytokine Signalling Forum
Latest Podcasts
Discussing Rheumatology: HZ and ILD with tofacitinib in RA
Prof Iain McInnes reviews two papers this month, and discusses the risk of herpes zoster (HZ) events in patients with RA treated with tofacitinib, as well as interstitial lung disease, an extra-articular manifestation of RA.
27th January 2022
Author Interview: Professor Kevin Winthrop (December 2021)
Professor Kevin Winthrop, Professor of Medicine at Oregon Health & Science University.
23rd December 2021
Discussing Rheumatology: Safety of filgotinib, and tofacitinib in pJIA
Prof Iain McInnes reviews two papers this month, and discusses exposure-adjusted incidence rates of TEAEs and AESIs with filgotinib, as well as the efficacy and safety of tofacitinib in pJIA.
23rd December 2021
Author Interview: Professor Kevin Winthrop (November 2021)
Professor Kevin Winthrop, Professor of Medicine at Oregon Health & Science University.
22nd December 2021
Discussing Rheumatology: Risk of HZ with UPA, and JAKs in SpA
Prof Iain McInnes reviews two papers this month, and discusses the increased risk of HZ infection with upadacitinib, as well as the role of the JAK-STAT pathway in SpA pathenogenesis.
06th December 2021
Author Interview: Professor Atul Deodhar
Professor Atul Deodhar, professor of medicine at Oregon Health & Science University.
06th December 2021
Author Interview: Professor Roy Fleischmann
Professor Roy Fleishmann, clinical professor of medicine at the University of Texas Southwestern Medical Center.
18th November 2021
Discussing Rheumatology: Herpes Zoster and HBV
Prof Iain McInnes discusses the risk of herpes zoster in RA patients taking biologics and DMARDS. He also discusses reactivation of hepatitis B in patients with RA taking tofacitinib.
31st October 2021
Rheumatology Author Professor Paul Bird: Tofacitinib Effectiveness
Paul Bird, Conjoint Professor at the University of South Wales joins Professor Peter Nash, where he discusses real-world data of tofacitinib therapy in RA
15th October 2021
Discussing Rheumatology: Poor Prognostic Factors, Monotherapy, and Combination Therapy
Prof Iain McInnes discusses poor prognostics factors from the FINCH 3 study, and the effectiveness and persistence of monotherapy and combination therapy from the Australian OPAL study.
23rd September 2021
